Pharming Group Dirección
Dirección controles de criterios 2/4
El CEO de Pharming Group's es Simon de Vries , nombrado en Nov 2008, tiene una permanencia de 15.42 años. compensación anual total es $2.81M, compuesta por 24% salario y 76% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.27% de las acciones de la empresa, por valor de €7.53M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 3.1 años, respectivamente.
Información clave
Simon de Vries
Chief Executive Officer (CEO)
US$2.8m
Compensación total
Porcentaje del salario del CEO | 24.0% |
Permanencia del CEO | 15.5yrs |
Participación del CEO | 1.3% |
Permanencia media de la dirección | 3.3yrs |
Promedio de permanencia en la Junta Directiva | 3.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price
Oct 29Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly
Jun 03Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)
May 12Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
Mar 15Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly
Feb 15Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Dec 31 2023 | US$3m | US$673k | -US$11m |
Sep 30 2023 | n/a | n/a | -US$22m |
Jun 30 2023 | n/a | n/a | -US$16m |
Mar 31 2023 | n/a | n/a | -US$2m |
Dec 31 2022 | US$2m | US$636k | US$14m |
Sep 30 2022 | n/a | n/a | US$30m |
Jun 30 2022 | n/a | n/a | US$21m |
Mar 31 2022 | n/a | n/a | US$11m |
Dec 31 2021 | US$3m | US$681k | US$16m |
Sep 30 2021 | n/a | n/a | US$22m |
Jun 30 2021 | n/a | n/a | US$31m |
Mar 31 2021 | n/a | n/a | US$37m |
Dec 31 2020 | US$3m | US$614k | US$38m |
Sep 30 2020 | n/a | n/a | US$44m |
Jun 30 2020 | n/a | n/a | US$46m |
Mar 31 2020 | n/a | n/a | US$42m |
Jan 01 2020 | n/a | n/a | US$41m |
Sep 30 2019 | n/a | n/a | US$38m |
Jun 30 2019 | n/a | n/a | US$34m |
Mar 31 2019 | n/a | n/a | US$29m |
Dec 31 2018 | US$2m | US$579k | US$29m |
Sep 30 2018 | n/a | n/a | -US$29m |
Jun 30 2018 | n/a | n/a | -US$44m |
Mar 31 2018 | n/a | n/a | -US$80m |
Dec 31 2017 | US$2m | US$537k | -US$91m |
Compensación vs. Mercado: La compensación total de Simon($USD2.81M) está por encima de la media de empresas de tamaño similar en el mercado Dutch ($USD1.44M).
Compensación vs. Ingresos: La compensación de Simon ha aumentado mientras la empresa no es rentable.
CEO
Simon de Vries (64 yo)
15.5yrs
Permanencia
US$2,809,000
Compensación
Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 15.5yrs | US$2.81m | 1.27% $ 7.7m | |
Chief Financial Officer | 3.5yrs | sin datos | 0.064% $ 386.9k | |
Chief Operations Officer | 4.8yrs | sin datos | 0.12% $ 717.5k | |
Investor Relations Manager | no data | sin datos | sin datos | |
Chief Ethics & Compliance Officer | 3yrs | sin datos | 0.025% $ 148.3k | |
Chief Medical Officer | 2.9yrs | sin datos | 0.027% $ 165.5k | |
Chief Commercial Officer & GM Americas | 7.3yrs | sin datos | 0.028% $ 168.5k | |
Chief Business Officer | less than a year | sin datos | 0.0097% $ 58.7k | |
Consultant | 2.9yrs | sin datos | sin datos |
3.3yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PHARM se considera experimentado (3.2 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
President | 15.6yrs | US$2.81m | 1.27% $ 7.7m | |
Independent Non-Executive Director | 3yrs | US$90.00k | 0.014% $ 85.0k | |
Independent Non-Executive Director | 3.4yrs | US$87.00k | 0.018% $ 107.3k | |
Independent Non-Executive Vice-Chairperson | 5yrs | US$87.00k | 0.020% $ 121.4k | |
Independent Non-Executive Director | 3yrs | US$90.00k | 0.014% $ 85.0k | |
Independent Non-Executive Director | 3.4yrs | US$94.00k | 0.018% $ 107.3k | |
Non-Executive Chairman of Board | less than a year | US$46.00k | 0.0041% $ 24.7k | |
Independent Non-Executive Director | 3yrs | US$94.00k | 0.014% $ 85.0k |
3.2yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de PHARM se considera experimentada (3.1 años de antigüedad promedio).